Please login to the form below

Not currently logged in
Email:
Password:

Tanzeum

This page shows the latest Tanzeum news and features for those working in and with pharma, biotech and healthcare.

Sanofi's lixisenatide is back under FDA review

Sanofi's lixisenatide is back under FDA review

Meanwhile, new GLP-1 agonists that require dosing just once a week - including Eli Lilly's Trulicity (dulaglutide), GlaxoSmithKline's Tanzeum (albiglutide) AstraZeneca's Bydureon (exenatide) and Novo Nordisk's semaglutide -

Latest news

  • Type 2 diabetes market set to hit $39bn by 2021 Type 2 diabetes market set to hit $39bn by 2021

    Notable examples include two recently approved once-weekly GLP-1 receptor agonists, Tanzeum and Trulicity, and an orally administered GLP-1 receptor agonist, OG-217SC, which is in phase II development,

  • Novo Nordisk's oral GLP-1 analogue looks set for phase III Novo Nordisk's oral GLP-1 analogue looks set for phase III

    If the injectable version is approved it will have to compete with a number of similar products on the market - notably AstraZeneca's Bydureon (exenatide), GlaxoSmithKline's Tanzeum/Eperzan (albiglutide) and

  • Novo Nordisk's Xultophy debuts in Switzerland Novo Nordisk's Xultophy debuts in Switzerland

    s Tanzeum (albiglutide), AstraZeneca's Bydureon (exenatide) and Eli Lilly's recently-launched Trulicity (dulaglutide) offering once-weekly rather than once-daily injections.

  • Lilly launches GLP-1 agonist Trulicity in US Lilly launches GLP-1 agonist Trulicity in US

    Once-weekly treatment will challenge GSK's Tanzeum, AZ's Bydureon and Novo's Victoza in diabetes.  . ... Lilly has launched Trulicity in the same price region as Victoza but above Tanzeum, which GSK is selling at a discount.

  • FDA approves Lilly’s GLP-1 diabetes drug Trulicity FDA approves Lilly’s GLP-1 diabetes drug Trulicity

    The once-weekly treatment is set to compete with Bydureon, Tanzeum and Victoza. ... Competition is heating up, however, and GlaxoSmithKline has won approval for once-weekly albiglutide in the US under the name Tanzeum and in the EU under the name Eperzan.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics